Evidence map›Paper›PMID 36292633›Full record

ReviewGenes2022

Rare Heterozygous

Evelien Van Dijck, Sigri Beckers, Sara Diels, Tammy Huybrechts, An Verrijken, Kim Van Hoorenbeeck, Stijn Verhulst, Guy Massa, Luc Van Gaal, Wim Van Hul

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Evelien Van DijckCentre of Medical Genetics, University of Antwerp and Antwerp University Hospital, 2650 Edegem, Belgium.
Sigri BeckersCentre of Medical Genetics, University of Antwerp and Antwerp University Hospital, 2650 Edegem, Belgium.ORCID 0000-0003-1097-141X
Sara DielsCentre of Medical Genetics, University of Antwerp and Antwerp University Hospital, 2650 Edegem, Belgium.
Tammy HuybrechtsCentre of Medical Genetics, University of Antwerp and Antwerp University Hospital, 2650 Edegem, Belgium.ORCID 0000-0001-6501-6714
An VerrijkenDepartment of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, 2650 Edegem, Belgium.
Kim Van HoorenbeeckDepartment of Pediatrics, Antwerp University Hospital, 2650 Edegem, Belgium.
Stijn VerhulstDepartment of Pediatrics, Antwerp University Hospital, 2650 Edegem, Belgium.ORCID 0000-0002-1922-9716
Guy MassaDepartment of Pediatrics, Jessa Hospital, 3500 Hasselt, Belgium.
Luc Van GaalDepartment of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, 2650 Edegem, Belgium.
Wim Van HulCentre of Medical Genetics, University of Antwerp and Antwerp University Hospital, 2650 Edegem, Belgium.ORCID 0000-0002-5065-7858
University of Antwerp · BEAntwerp University Hospital · BEJessa Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, it was reported that heterozygous PCSK1 variants, causing partial PC1/3 deficiency, result in a significant increased risk for obesity. This effect was almost exclusively generated by the rare p.Y181H (rs145592525, GRCh38.p13 NM_000439.5:c.541T>C) variant, which affects PC1/3 maturation but not enzymatic capacity. As most of the identified individuals with the heterozygous p.Y181H variant were of Belgian origin, we performed a follow-up study in a population of 481 children and adolescents with obesity, and 486 lean individuals. We identified three obese (0.62%) and four lean (0.82%) p.Y181H carriers (p = 0.506) through sanger sequencing and high resulting melting curve analysis, indicating no association with obesity. Haplotype analysis was performed in 13 p.Y181H carriers, 20 non-carriers (10 with obesity and 10 lean), and two p.Y181H families, and showed identical haplotypes for all heterozygous carriers (p < 0.001). Likewise, state-of-the-art literature concerning the role of rare heterozygous PCSK1 variants implies them to be rarely associated with monogenic obesity, as first-degree carrier relatives of patients with PC1/3 deficiency are mostly not reported to be obese. Furthermore, recent meta-analyses have only indicated a robust association for scarce disruptive heterozygous PCSK1 variants with obesity, while clinical significance is less or sometimes lacking for most nonsynonymous variants.

Indexed as

ObesityProprotein Convertase 1AdolescentChildFollow-Up StudiesHeterozygoteHumansPCSK1 protein, humanProprotein Convertase 1founder mutationobesityoverweightproprotein convertase subtilisin/kexin type 1 (PCSK1)rare variants

Identifiers

PMID36292633
PMCPMC9601648
OpenAlexW4297349560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.